Alzheimer’s disease in the elderly can be diagnosed through blood tests. The Department of Biophysics, AIIMS, in collaboration with the Department of Geriatric Medicine and Neurology, has discovered a diagnostic blood protein for early diagnosis of Alzheimer’s disease.
With the help of this, it will be known whether the elderly have Alzheimer’s disease or not. If it is about to start, the symptoms are also known from this test. For this study, AIIMS selected more than 100 elderly people who come to the Geriatrics Department.
During the study period of about three years, their blood samples were taken and tested. During the research, a new protein called sirtuin was identified in the blood of Alzheimer’s disease, which gradually decreases in the patient over time and damages the body.
In this test, sirtuin protein was used to diagnose Alzheimer’s disease. In this regard, Professor Dr. Sharmistha Dey, Department of Biophysics, AIIMS said that this research will bring relief to thousands of elderly people in the country. Until now, the diagnosis of Alzheimer’s has been made by examination of the cerebrospinal fluid (CSF test), which only gives results after a long period of time.
Used it in new method
The method of diagnosing Alzheimer’s disease based on blood tests has been used to investigate various biological molecules that play a role in the pathophysiology of Alzheimer’s disease. This could be the reason for Alzheimer’s disease. Identifying protein markers in the blood may be more beneficial than the CFF test. Blood can be easily drawn from an elderly patient. While it is very difficult for CSF to extract fluid from the spinal cord of elderly patients.
Delayed treatment becomes difficult
Alzheimer’s disease (AD) is one of the most underdiagnosed geriatric syndromes in India. It is important to get caught early for its treatment. With this disease, the memory of the elderly becomes weak. At the same time, the ability to make the brain work decreases. For the treatment of the disease, it is necessary to catch it at the initial stage. Currently available technology detects the disease using cerebrospinal fluid (CSF) biomarkers. It measures total tau, phospho-tau and 42 amino acids of β-amyloid (A beta 42) to detect Alzheimer’s disease.